blue digital circular waveforms

Press Releases

March 19, 2024

iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists

Newly released capabilities — limiting the number of marks on a 3D view, color-coding lesion marks, and color-coding the ProFound Scorecard — enhance radiologists’ interpretability and efficiency NASHUA, N.H. – March 19, 2024 – iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers…

March 12, 2024

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year Year ending cash balance of $21.7M NASHUA, N.H. – March 12, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical…

February 28, 2024

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

NASHUA, N.H. – Feb. 28, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, will highlight scientific presentations, including an award-winning poster at the European Congress of Radiology (ECR) annual…

February 27, 2024

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NASHUA, NH., February 27, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year…

February 27, 2024

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, Dr.h.cm

Dr. Hricak offers extensive experience in radiology, real world application of AI enabled imaging solutions, research, and global healthcare perspectives. NASHUA, NH., February 27, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect…

February 6, 2024

iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

NASHUA, NH., February 6, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will participate in the BTIG at Snowbird: 11th Annual MedTech, Digital…

January 30, 2024

iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member

NASHUA, NH., January 30, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Michael J. Doyle to its Board of Directors, effective immediately….

December 18, 2023

iCAD Expands Executive Sales Leadership Team as Business Grows

Bill Keyes shifts and expands his role to Senior Vice President, Global Sales Operations and Peter Graham joins iCAD as Senior Vice President, North American Sales to accelerate growth while organization adds new products and partnerships. NASHUA, N.H., December 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology…

November 28, 2023

iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare

NASHUA, N.H., Nov. 28, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence (AI) powered solutions from iCAD’s ProFound Breast Health Suite are the first applications to be offered in GE HealthCare’s new MyBreastAI Suite* offering. As breast…

November 27, 2023

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

NASHUA, N.H. – Nov. 27, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, will present new studies validating its artificial intelligence (AI) powered  ProFound Breast Health Suite for uncovering hidden heart or vascular disease and predicting a woman’s risk for developing breast cancer…